| Literature DB >> 35436936 |
Nanor Minoyan1,2, Stine Bordier Høj1, Camille Zolopa1, Dragos Vlad1,2, Julie Bruneau1,3, Sarah Larney4,5.
Abstract
BACKGROUND: People who use drugs (PWUD) are at high risk of experiencing indirect harms of measures implemented to curb the spread of COVID-19, given high reliance on services and social networks. This study aimed to document short-term changes in behaviours and health-related indicators among PWUD in Montreal, Canada following declaration of a provincial health emergency in Quebec.Entities:
Keywords: Access to health services; COVID-19; Drug markets; Drug-related harms; Harm reduction; People who use drugs; Rapid assessment
Mesh:
Substances:
Year: 2022 PMID: 35436936 PMCID: PMC9013973 DOI: 10.1186/s12954-022-00620-w
Source DB: PubMed Journal: Harm Reduct J ISSN: 1477-7517
Participant characteristics (N = 227)
| Age, median [ | 46 [39–56] |
| Male | 174 (76.7) |
| Female | 49 (21.6) |
| Other | 4 (1.8) |
| White/Caucasian | 182 (80.9) |
| Indigenous | 12 (5.3) |
| Other | 31 (13.8) |
| Recent unstable housingb | 83 (36.6) |
| Survivalc income source(s) in the 3 months prior to pandemic | 40 (17.6) |
| Diagnosed with ≥ 1 chronic physical conditiond | 133 (58.8) |
| Living with a mental disorder, or a serious mental health problem | 94 (41.4) |
| Opioid agonist treatment, current | 69 (30.4) |
| Alcohol use, past 6 months | 159 (70.0) |
| Illicit drug use, past 6 months | 188 (82.8) |
| Opioid | 35 (15.4) |
| Stimulant | 93 (41.0) |
| Alcohol | 36 (15.9) |
| Cannabis | 52 (22.9) |
| Ketamine | 2 (0.9) |
| None | 7 (3.1) |
| Injection drug use, past 6 months | 94 (41.4) |
| Heroin | 52 (55.3) |
| Prescription opioids | 32 (34.0) |
| Cocaine | 47 (50.0) |
| Amphetamine | 13 (13.8) |
| Both opioid & stimulant | 27 (28.7) |
| Other | 5 (5.3) |
a2 missing values
bQuestion pertained to the 6 months preceding the interview in May–June 2020, and the period since the pandemic (ranging from 6 to 9 months prior to the interview) in September–December 2020
cReporting income from informal or street-based income generation activities, e.g. panhandling, sex work, recycling, pawning
dSelf-reported lifetime diagnosis of: lung disease, diabetes, cardiovascular disease, chronic liver or kidney disease, HIV, HCV, or other condition affecting immune system
e% calculated among people reporting past six-month injection drug use (n = 94)
Access to health services and opioid agonist treatment
| Overall sample | |
|---|---|
|
| |
| Harder | 119 (52.4) |
| Easier | 10 (4.4) |
| Same as usual | 42 (18.5) |
| Don’t know | 55 (24.2) |
|
| |
| Harder | 95 (41.9) |
| Easier | 6 (2.6) |
| Same as usual | 44 (19.4) |
| Don’t know | 81 (35.7) |
|
| |
| Harder | 94 (41.4) |
| Easier | 3 (1.3) |
| Same as usual | 35 (15.4) |
| Don’t know | 93 (41.0) |
|
| |
| Harder | 82 (36.1) |
| Easier | 2 (0.9) |
| Same as usual | 34 (15.0) |
| Don’t know | 106 (46.7) |
OAT, opioid agonist treatment
a% calculated among people reporting at least one strategy (n = 33)
Changes in ability to meet survival-related needs (N = 227)
| Any change in living situation | 73 (32.2) |
|
| |
| Worse | 26 (35.6) |
| Better | 34 (46.6) |
| About the same | 11 (15.1) |
| Don’t know/missing | 2 (2.7) |
| Became homeless as a result of the COVID-19 crisis | 42 (18.5) |
| More difficult | 58 (69.9) |
| Easier | 2 (2.4) |
| Same as usual | 11 (13.3) |
| Don’t know/not applicable | 12 (14.5) |
| Decreased | 82 (36.1) |
| Increased | 38 (16.7) |
| Not changed | 105 (46.3) |
| Don’t know | 2 (0.9) |
a % calculated among those experiencing any change in living situation (n = 73)
b1 missing value
Changes in risk environments, drug markets and drug use patterns
| Overall sample | |
|---|---|
| Increased | 93 (41.0) |
| Decreased | 19 (8.4) |
| Not changed | 94 (41.4) |
| Don't know/refused/not applicablea | 21 (9.3) |
| Increased | 66 (29.1) |
| Decreased | 14 (6.2) |
| Not changed | 122 (53.7) |
| Don't know/refused/not applicablea | 25 (11.0) |
| Increased | 48 (21.2) |
| Decreased | 14 (6.2) |
| Not changed | 14 (6.2) |
| Don't know/refused/not applicablea | 27 (11.9) |
| Increased | 86 (37.9) |
| Decreased | 5 (2.2) |
| Not changed | 35 (15.4) |
| Doesn’t know | 101 (44.5) |
| Has heard of new drugs coming into the market | 42 (18.5) |
| Increased | 81 (35.7) |
| Decreased | 52 (22.9) |
| Not changed | 94 (41.4) |
| Increased | 36 (15.9) |
| Decreased | 32 (14.1) |
| Not changed | 158 (69.6) |
aNot applicable (N/A) response option added in September–December
b1 missing value
c% calculated among those experiencing any drug market related change (n = 43)
Drug-related risk behaviours and adverse health outcomes
| Overall sample | |
|---|---|
| Bought drugs from a new dealera | 106 (46.7) |
| Increased | 20 (11.9) |
| Decreased | 6 (3.6) |
| Not changed | 142 (84.5) |
| Overdosed by accident | 19 (8.4) |
| Increased | 9 (4.0) |
| Decreased | 9 (4.0) |
| Not changed | 207 (91.2) |
| Don’t know | 2 (0.88) |
| Has been feeling more depressed or anxious than usual | 133 (58.6) |
aDenominators exclude participants reporting “don’t know” or “not applicable” (n = 68); many participants felt this question did not pertain to them, as they did not use opioids
bDenominators exclude missing values (maximum n = 3)